Latest News as of 13-05-2024

OXBRYTA (Voxelotor tablets)


Approval by NICE on 03/05/2024

The National Institute for Health and Care Excellence (NICE) has approved Voxelotor (Oxbryta) for use in people living with sickle cell disorder (SCD) on Friday 3 May 2024.

Voxelotor was initially rejected by NICE in July 2023, has now received an approval following a successful appeal..

This is great win for people with sickle cell disease, particularly given the health inequalities experienced by people with the condition in the UK – a breakthrough in the fight for equitable access to safe and effective treatments;
We at AOFAC Foundation are proud to be part of this achievement

This drug has transformed the way people living with the condition are able to live their lives, bringing improvements in physical and mental health.
Voxelotor will be funded immediately via NHS England’s Innovative Medicines Fund.

Can read details from NICE news article :